AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01610856
Drug: polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol 4L given in two split doses of 2L each
Trial: NCT03735082
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apatinib 250mg,qd,d1-14,14day/cycle
Trial: NCT03735082
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: paclitaxel 175mg/m2,d1,14day/cycle+carboplatin AUC=4,d1,14day/cycle
Trial: NCT03735082
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: carboplatin AUC=4,d1,14day/cycle;
Trial: NCT00036088
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02710578
Drug: Alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single oral administration of an alcoholic beverage mixed in a 1:3 ratio of alcohol (Vodka) to tonic water to obtain a target BAC of 0.08mg%
Trial: NCT01808144
Drug: lesinurad
RxNorm normalized name: Lesinurad
DrugBank: Lesinurad (DB11560)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets, 400 mg once daily (QD)
Trial: NCT01808144
Drug: lesinurad
RxNorm normalized name: Lesinurad
DrugBank: Lesinurad (DB11560)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets, 200 mg QD
Trial: NCT01808144
Drug: febuxostat
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tabletsm 80 mg QD
Trial: NCT02724163
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Antibody-conjugated chemotherapy agent.
Trial: NCT02724163
Drug: Liposomal daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Anthracycline~(Randomisation 1 (R1)) closed early to recruitment on 8th September 2017, due to liposomal daunorubicin manufacturing issues resulting in unavailability of the drug.
Trial: NCT02724163
Drug: Mitoxantrone
RxNorm normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DNA-reactive agent
Trial: NCT02724163
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A water-soluble fluorinated nucleotide analogue of the antiviral agent vidarabine.
Trial: NCT02724163
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pyrimidine nucleoside analogue, an antineoplastic agent.
Trial: NCT02724163
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alkylsulfonate
Trial: NCT00292708
Drug: Cefmetazole (drug)
RxNorm normalized name: Cefmetazole
DrugBank: Cefmetazole (DB00274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01152996
Drug: Vortioxetine
RxNorm normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vortioxetine tablets
Trial: NCT00816127
Drug: Desmopressin
RxNorm normalized name: Desmopressin
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intranasal desmopressin (300μg)
Trial: NCT01241708
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib 1.6mg/m2 on day -4 and day -1
Trial: NCT00169104
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 mcgm/kg daily Monday through Friday weeks 3-14
Trial: NCT00169104
Drug: trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4 mcgm/kg intravenously (IV) over 90 minutes week 1, then 2 mg/kg IV over 30 minutes weeks 2-14
Trial: NCT00169104
Drug: vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg/m2 over 6 minutes IV weekly, weeks 3, 4, 6, 7, 9, 10, 12, 13
Trial: NCT00169104
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 mcgm/kg SQ daily for ten days, Monday through Friday of the first two weeks of the study
Trial: NCT00576862
Drug: INSULIN GLARGINE
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The subjects will continue the treatment with HOE 901 in the same way as they have done in the previous study. Based on the investigator's assessment and the approved SPC in Belgium/Luxembourg, the dosage can be adjusted individually. HOE 901 is to be injected once daily. HOE 901 must not be mixed with any other insulin, including regular human insulin or fast-acting insulin analogues.
Trial: NCT00463918
Drug: varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01178125
Drug: DR-102
RxNorm normalized name: Dr. Numb
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03227731
Drug: Truvada
RxNorm normalized name: Truvada
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Truvada (Truvada (emtricitabine 200mg/tenofovir disoproxil fumarate 300mg) is in a fixed-dose combination (FDC) tablet formulation and is proven safe for the prevention and treatment of HIV in non-pregnant and non-lactating women.
Trial: NCT02956538
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02956538
Drug: placebo(for thalidomide)
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: sugar pill manufactured to mimic thalidomide 100mg tablet
Trial: NCT00248157
Drug: Octreotide acetate in microspheres
RxNorm normalized name: Octreotide Acetate
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01726075
Drug: Brimonidine
RxNorm normalized name: Brimonidine
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One drop per eye twice a day during 24 months
Trial: NCT03410992
Drug: Bimekizumab
RxNorm normalized name: bimekizumab
DrugBank: Bimekizumab (DB12917)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Bimekizumab will be provided at pre-specified time intervals.
Trial: NCT03050177
Drug: Gefitinib Tablet 250mg of Hunan Kelun
RxNorm normalized name: gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of Gefitinib Tablet 250mg of Hunan Kelun was administered under fed conditions after a 10-hour overnight fast.
Trial: NCT01280526
Drug: Romidepsin and CHOP
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
Trial: NCT01028404
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: As an active comparator, one standard dose will be given s.c. (under the skin) at all dose levels.
Trial: NCT01028404
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: As an active comparator, one standard dose will be given s.c. (under the skin) at one study visit.
Trial: NCT01733121
Drug: NBI-98854
RxNorm normalized name: NBI-98782
DrugBank: NBI-98782 (DB16905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg capsule
Trial: NCT01733121
Drug: NBI-98854
RxNorm normalized name: NBI-98782
DrugBank: NBI-98782 (DB16905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg capsule
Trial: NCT02602314
Drug: Imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02602314
Drug: Nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02533934
Drug: Harvoni
RxNorm normalized name: Harvoni
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment of Hepatitis C with sofosbuvir based HCC therapy
Trial: NCT00905424
Drug: Antidepressant + SPD489 (lisdexamfetamine dimesylate)
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Escitalopram oxalate (antidepressant) 20 mg/day oral + 20, 30, or 50 mg SPD489 oral once daily for 6 weeks
Trial: NCT03307941
Drug: Monalizumab
RxNorm normalized name: Monalizumab
DrugBank: Monalizumab (DB12824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monalizumab (IPH2201) is given at the recommended dose of 10 mg/kg, intravenously (infusion during 60 minutes) every two weeks
Trial: NCT03307941
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A total of 4 cycles of FOLFOX is administrated every 2 weeks with one cycle 15 days prior to the radiotherapy and 3 cycles during the radiotherapy whatever the level
Trial: NCT03307941
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A total of 4 cycles of FOLFOX is administrated every 2 weeks with one cycle 15 days prior to the radiotherapy and 3 cycles during the radiotherapy whatever the level
Trial: NCT01585246
Drug: Saw Palmetto
RxNorm normalized name: Saw palmetto
DrugBank: Saw palmetto (DB14360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 of 3 doses of Saw Palmetto (320, 640, 960mg/day)
Trial: NCT01585246
Drug: soybean oil soft gel
RxNorm normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (soybean oil soft gel)
Trial: NCT02420262
Drug: insulin degludec/liraglutide
RxNorm normalized name: INSULIN DEGLUDEC/LIRAGLUTIDE
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Once daily injected s.c./subcutaneously (under the skin) in combination with metformin.
Trial: NCT02420262
Drug: insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Once daily injected s.c./subcutaneously (under the skin) in combination with metformin.
Trial: NCT02420262
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Injected s.c./subcutaneously (under the skin) before each main meal.
Trial: NCT00624000
Drug: IV tpa (Alteplase) vs IA tpa (Alteplase)
RxNorm normalized name: tPA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alteplase was administered Either IA or IV x 1
Trial: NCT04229706
Drug: High dose Xiang Ju Ru Pi Ning capsule
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: xingjurupining capsule,8 capsule,tid,3 months.
Trial: NCT04229706
Drug: Low dose Xiang Ju Ru Pi Ning capsule
RxNorm normalized name: low-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: xiangjurupining capsule,4 capsules , and xiangjurupining capsule placebo,4 capsules,tid,3 months.
Trial: NCT03891433
Drug: Meropenem
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbapenems group intervention.
Trial: NCT03891433
Drug: Ertapenem 1000 MG
RxNorm normalized name: ertapenem 1000 MG
DrugBank: Ertapenem (DB00303)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Carbapenems group intervention.
Trial: NCT03891433
Drug: Piperacillin, Tazobactam 4-0.5G Solution for Injection
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piperacillin/Tazobactam group intervention.
Trial: NCT01852513
Drug: QNASL
RxNorm normalized name: Qnasl
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00371813
Drug: Varenicline tartrate
RxNorm normalized name: Varenicline tartrate
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02485613
Drug: bortezominb and dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The initial BD regimen included bortezomib (1.3 mg/m2 i.v.) and dexamethasone (40 mg i.v.) twice weekly for 2 weeks (days 1, 4, 8, and 11), which was followed by a 10-day rest period (days 12-21). The dose of bortezomib and dexamethasone can be adjusted according to the patients' condition.
Trial: NCT02215616
Drug: Laquinimod
RxNorm normalized name: laquinimod
DrugBank: Laquinimod (DB06685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laquinimod capsules will be administered as per the dose and schedule specified in the respective arms.
Trial: NCT00324740
Drug: vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00324740
Drug: isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00124813
Drug: thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00124813
Drug: idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral idarubicin
Trial: NCT02539719
Drug: SC-003 in combination with ABBV-181
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01594346
Drug: Alpha-Tocopherol
RxNorm normalized name: Alpha-tocopherol
DrugBank: alpha-Tocopherol succinate (DB14001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 International Units, two times a day for 36 months
Trial: NCT01594346
Drug: Sugar Pill
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00639262
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib 200mg twice daily during XRT and 30 days after. (Sorafenib will be escalated for both cohorts to determine maximum tolerated dose)
Trial: NCT00639262
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For Cohort 2 - Gliomas only.
Trial: NCT01818986
Drug: Sipuleucel-T
RxNorm normalized name: Sipuleucel-T
DrugBank: Sipuleucel-T (DB06688)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03582917
Drug: Alphacalcidol
RxNorm normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alphacalcidol 0,5mg tablet
Trial: NCT00278863
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT00596050
Drug: ketamine and midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ketamine 1 mg/kg/dose, midazolam 0.05 mg/kg/dose max 2 mg
Trial: NCT00596050
Drug: etomidate, fentanyl, and lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: etomidate 0.2 mg/kg/dose, fentanyl 1 microgram/kg/dose, lidocaine 0.5 mg/kg/dose
Trial: NCT01566422
Drug: Vancomycin powder
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients randomized to this group will receive vancomycin powder in the surgical incision after posterior spinal fusion.
Trial: NCT04435522
Drug: Maraviroc
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maraviroc will be administered for seven days. Biomarkers of disease will be checked at time of enrollment, during and at the conclusion of therapy. The cytokine panel will consist of CCL5, IL-6, and Chitinase 3-like 1(Chi3l1).
Trial: NCT02074878
Drug: Crixotinib 200 mg and Sunitinib Cohort 1
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Crizotinib 200 mg, twice daily with Sunitinib 25.0 mg once a day
Trial: NCT02074878
Drug: Crixotinib 250 mg and Sunitinib Cohort 2
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Crizotinib 250 mg, twice daily with Sunitinib 25.0 mg once a day
Trial: NCT02074878
Drug: Crizotinib & Sunitinib 37.5 mg Cohort 3
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Crizotinib 250 mg, twice daily with Sunitinib 37.5 mg once a day
Trial: NCT01874522
Drug: TAS-102 tablets
RxNorm normalized name: Ta
DrugBank: TAS-102 (DB08937)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover bioavailability part: 60 mg/dose, orally, up to 2 single doses separated by 1-week washout.~Extension part: 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
Trial: NCT01874522
Drug: TAS-102 oral solution
RxNorm normalized name: Ta
DrugBank: TAS-102 (DB08937)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/dose, orally, up to 2 single doses separated by 1-week washout
Trial: NCT03925402
Drug: Ertapenem
RxNorm normalized name: Ertapenem
DrugBank: Ertapenem (DB00303)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ertapenem injection
Trial: NCT03925402
Drug: Carbapenems
RxNorm normalized name: Carbapenems
DrugBank: Carbapenem (DB18912)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other carbapenems injection
Trial: NCT01204086
Drug: Venlafaxine
RxNorm normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The initial dose of venlafaxine was 37.5 mg once daily for 4 days titrated to 75 mg once daily, which could be increased by 75 mg in divided doses to a maximal daily dose of 225 mg.
Trial: NCT01818973
Drug: Xeloda
RxNorm normalized name: Xeloda
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning, 8 cycles
Trial: NCT01818973
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: iv, 130mg/m2, day 1, 1 cycle during neoadjuvant chemotherapy and 3 cycles in adjuvant chemotherapy 100mg/m2, day 1, 2 cycles during concurrent chemoradiotherapy
Trial: NCT01818973
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: iv, 7.5 mg/kg, day 1, 3 cycles during neoadjuvant chemotherapy and concurrent chemoradiotherapy
Trial: NCT03320174
Drug: Tafenoquine
RxNorm normalized name: tafenoquine
DrugBank: Tafenoquine (DB06608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tafenoquine 200mg
Trial: NCT03135509
Drug: CC-220
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-220 gelatin capsules
Trial: NCT03789097
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg administered as an IV infusion over 30 minutes Q3W
Trial: NCT03789097
Drug: Poly ICLC
RxNorm normalized name: Poly iclc
DrugBank: Hiltonol (DB17293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an immune cell activating factor. vials containing 1 ml of 2 mg/mL
Trial: NCT03162185
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental group participants (n = 30) will receive 20 mg of Escitalopram for 7 days.
Trial: NCT02686164
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib 24 mg (as one 4 mg and two 10 mg capsules) will be administered orally once daily with 240 mL (8 fluid oz) of water each morning, starting on Cycle 1 Day 1, in 28-day cycles.
Trial: NCT02686164
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam syrup 4 mg will be administered orally after an overnight fast on Cycle 1 Day -3 and concurrently with lenvatinib on Day 1 and Day 14 of Cycle 1. Participants will have to remain fasting for 2 hours after each dose of midazolam.
Trial: NCT00805129
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus (RAD001) is a novel oral derivative of rapamycin. Everolimus will be administered orally as a once-daily dose of 10 mg (two 5 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take Everolimus in the morning, at the same time each day. Everolimus should be taken by the patient in a fasting state or with no more than a light fat-free meal.
Trial: NCT00563615
Drug: Tegaserod
RxNorm normalized name: Tegaserod
DrugBank: Tegaserod (DB01079)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01067534
Drug: Salbutamol
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaler salbutamol 0,1 mg/dose - 4 doses=0,4 mg
Trial: NCT00647972
Drug: Olanzapine Tablets 20 mg
RxNorm normalized name: olanzapine Oral Tablet
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg, single dose fasting